{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:20:53Z","timestamp":1793496053580,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006545","name":"U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["R01MD017529"],"award-info":[{"award-number":["R01MD017529"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["R01MD017529"],"award-info":[{"award-number":["R01MD017529"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["R01MD017529"],"award-info":[{"award-number":["R01MD017529"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["R01MD017529"],"award-info":[{"award-number":["R01MD017529"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["R01MD017529"],"award-info":[{"award-number":["R01MD017529"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["R01MD017529"],"award-info":[{"award-number":["R01MD017529"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["R01MD017529"],"award-info":[{"award-number":["R01MD017529"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41591-026-04504-5","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:44:46Z","timestamp":1782985486000},"page":"2933-2940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9651-3836","authenticated-orcid":false,"given":"Ambarish","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Keshvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed K.","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Khashami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Yaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shariq","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Segar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3432-2667","authenticated-orcid":false,"given":"Anand K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan David","family":"Coellar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Bustillo-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-0146","authenticated-orcid":false,"given":"Zachary L.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer T.","family":"Thibodeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Drazner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Tarique","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4878-891X","authenticated-orcid":false,"given":"Vlad G.","family":"Zaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4063-6508","authenticated-orcid":false,"given":"Thomas J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"4504_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.cardfail.2025.07.007","volume":"32","author":"G Fonarow","year":"2026","unstructured":"Fonarow, G. et al. Heart failure epidemiology and outcomes statistics an updated 2025 report from the Heart Failure Society of America. J. Card. Fail. 32, 439\u2013498 (2026).","journal-title":"J. Card. Fail."},{"key":"4504_CR2","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 79, e263\u2013e421 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4504_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","volume":"396","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan, M. et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396, 121\u2013128 (2020).","journal-title":"Lancet"},{"key":"4504_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1161\/CIRCULATIONAHA.123.067489","volume":"149","author":"A Sumarsono","year":"2024","unstructured":"Sumarsono, A. et al. Sex disparities in longitudinal use and intensification of guideline-directed medical therapy among patients with newly diagnosed heart failure with reduced ejection fraction. Circulation 149, 510\u2013520 (2024).","journal-title":"Circulation"},{"key":"4504_CR5","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.jchf.2023.08.027","volume":"12","author":"A Mentias","year":"2024","unstructured":"Mentias, A. et al. Patterns, prognostic implications, and rural-urban disparities in optimal GDMT following HFrEF diagnosis among Medicare beneficiaries. JACC Heart Fail. 12, 1044\u20131055 (2024).","journal-title":"JACC Heart Fail."},{"key":"4504_CR6","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/ejhf.3267","volume":"26","author":"J Malgie","year":"2024","unstructured":"Malgie, J. et al. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study. Eur. J. Heart Fail. 26, 1549\u20131560 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"4504_CR7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jchf.2024.03.001","volume":"12","author":"SJ Greene","year":"2024","unstructured":"Greene, S. J. et al. Eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed heart failure. JACC Heart Fail. 12, 1365\u20131377 (2024).","journal-title":"JACC Heart Fail."},{"key":"4504_CR8","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa, A. et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400, 1938\u20131952 (2022).","journal-title":"Lancet"},{"key":"4504_CR9","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jchf.2023.06.022","volume":"11","author":"SA Swat","year":"2023","unstructured":"Swat, S. A. et al. Clinical inertia among outpatients with heart failure: application of treatment nonintensification taxonomy to EPIC-HF trial. JACC Heart Fail. 11, 1579\u20131591 (2023).","journal-title":"JACC Heart Fail."},{"key":"4504_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jchf.2023.03.007","volume":"11","author":"MS Khan","year":"2023","unstructured":"Khan, M. S. et al. Polypharmacy and optimization of guideline-directed medical therapy in heart failure. The GUIDE-IT trial. JACC Heart Fail. 11, 1507\u20131517 (2023).","journal-title":"JACC Heart Fail."},{"key":"4504_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012547","volume":"18","author":"AJ Sauer","year":"2025","unstructured":"Sauer, A. J. et al. Multiregional implementation initiative\u2019s impact on guideline-based performance measures for patients hospitalized with heart failure: IMPLEMENT-HF. Circ. Heart. Fail. 18, e012547 (2025).","journal-title":"Circ. Heart. Fail."},{"key":"4504_CR12","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/ejhf.2163","volume":"23","author":"AS Bhatt","year":"2021","unstructured":"Bhatt, A. S. et al. Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study. Eur. J. Heart Fail. 23, 1191\u20131201 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"4504_CR13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jchf.2024.08.017","volume":"13","author":"A Spahillari","year":"2025","unstructured":"Spahillari, A. et al. Efficacy, safety and mechanistic impact of a heart failure guideline-directed medical therapy clinic. JACC Heart Fail. 13, 554\u2013568 (2025).","journal-title":"JACC Heart Fail."},{"key":"4504_CR14","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.jacc.2022.03.338","volume":"79","author":"L Ghazi","year":"2022","unstructured":"Ghazi, L. et al. Electronic alerts to improve heart failure therapy in outpatient practice: a cluster randomized trial. J. Am. Coll. Cardiol. 79, 2203\u20132213 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4504_CR15","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1815359","volume":"381","author":"D Munoz","year":"2019","unstructured":"Munoz, D. et al. Polypill for cardiovascular disease prevention in an underserved population. N. Engl. J. Med. 381, 1114\u20131123 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4504_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1056\/NEJMoa2208275","volume":"387","author":"JM Castellano","year":"2022","unstructured":"Castellano, J. M. et al. Polypill strategy in secondary cardiovascular prevention. N. Engl. J. Med. 387, 967\u2013977 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4504_CR17","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1002\/ejhf.70031","volume":"27","author":"PM Seferovic","year":"2025","unstructured":"Seferovic, P. M. et al. Contemporary implementation of guideline-directed medical and device therapies in heart failure: Insights from the Central\/Eastern Europe Quality of Care Centres Survey. Eur. J. Heart Fail. 27, 1977\u20131991 (2025).","journal-title":"Eur. J. Heart Fail."},{"key":"4504_CR18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jchf.2023.04.017","volume":"11","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt, B. et al. Mortality, outcomes, costs, and use of medicines following a first heart failure hospitalization: EVOLUTION HF. JACC Heart Fail. 11, 1320\u20131332 (2023).","journal-title":"JACC Heart Fail."},{"key":"4504_CR19","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1093\/eurheartj\/ehaf244","volume":"46","author":"J Malgie","year":"2025","unstructured":"Malgie, J. et al. Newly diagnosed heart failure with reduced ejection fraction: timing, sequencing, and titration of guideline-recommended medical therapy. Eur. Heart J. 46, 2394\u20132405 (2025).","journal-title":"Eur. Heart J."},{"key":"4504_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","volume":"56","author":"DG Kramer","year":"2010","unstructured":"Kramer, D. G. et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J. Am. Coll. Cardiol. 56, 392\u2013406 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4504_CR21","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1093\/eurheartj\/ehae334","volume":"45","author":"C Veltmann","year":"2024","unstructured":"Veltmann, C. et al. Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study. Eur. Heart J. 45, 2771\u20132781 (2024).","journal-title":"Eur. Heart J."},{"key":"4504_CR22","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk, G. D. & Verma, S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors. A state-of-the-art review. JACC Basic Transl. Sci. 5, 632\u2013644 (2020).","journal-title":"JACC Basic Transl. Sci."},{"key":"4504_CR23","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1093\/eurheartj\/ehad522","volume":"44","author":"M Banerjee","year":"2023","unstructured":"Banerjee, M., Maisnam, I., Pal, R. & Mukhopadhyay, S. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis. Eur. Heart J. 44, 3686\u20133696 (2023).","journal-title":"Eur. Heart J."},{"key":"4504_CR24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0140-6736(19)31791-X","volume":"394","author":"G Roshandel","year":"2019","unstructured":"Roshandel, G. et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 394, 672\u2013683 (2019).","journal-title":"Lancet"},{"key":"4504_CR25","doi-asserted-by":"publisher","first-page":"e093663","DOI":"10.1136\/bmjopen-2024-093663","volume":"15","author":"C DeJong","year":"2025","unstructured":"DeJong, C. et al. Delivering guideline-directed medical therapy for heart failure with reduced ejection fraction as an over-encapsulated polypill: rationale and protocol for the COMBO-HF-X pilot crossover randomised clinical trial. BMJ Open 15, e093663 (2025).","journal-title":"BMJ Open"},{"key":"4504_CR26","doi-asserted-by":"publisher","first-page":"e100952","DOI":"10.1136\/bmjopen-2025-100952","volume":"15","author":"A Agarwal","year":"2025","unstructured":"Agarwal, A. et al. Heart failure with reduced ejection fraction polypill implementation strategy in Sri Lanka: design and protocol of a pilot type I hybrid randomised clinical trial. BMJ Open 15, e100952 (2025).","journal-title":"BMJ Open"},{"key":"4504_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007264","volume":"13","author":"A Nayak","year":"2020","unstructured":"Nayak, A., Hicks, A. J. & Morris, A. A. Understanding the complexity of heart failure risk and treatment in Black patients. Circ. Heart Fail. 13, e007264 (2020).","journal-title":"Circ. Heart Fail."},{"key":"4504_CR28","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa0807265","volume":"360","author":"K Bibbins-Domingo","year":"2009","unstructured":"Bibbins-Domingo, K. et al. Racial differences in incident heart failure among young adults. N. Engl. J. Med. 360, 1179\u20131190 (2009).","journal-title":"N. Engl. J. Med."},{"key":"4504_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamacardio.2022.0161","volume":"7","author":"EM DeFilippis","year":"2022","unstructured":"DeFilippis, E. M. et al. Improving enrollment of underrepresented racial and ethnic populations in heart failure trials: a call to action from the heart failure collaboratory. JAMA Cardiol. 7, 540\u2013548 (2022).","journal-title":"JAMA Cardiol."},{"key":"4504_CR30","doi-asserted-by":"publisher","unstructured":"Keshvani, N. et al. Rationale, design, and baseline characteristics of the polypill for heart failure with reduced ejection fraction (POLY-HF) trial. J. Card. Fail. https:\/\/doi.org\/10.1016\/j.cardfail.2025.10.008 (2025).","DOI":"10.1016\/j.cardfail.2025.10.008"},{"key":"4504_CR31","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","volume":"38","author":"W Ouwerkerk","year":"2017","unstructured":"Ouwerkerk, W. et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur. Heart J. 38, 1883\u20131890 (2017).","journal-title":"Eur. Heart J."},{"key":"4504_CR32","doi-asserted-by":"crossref","unstructured":"The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am. J. Cardiol. 78, 902\u2013907 (1996).","DOI":"10.1016\/S0002-9149(96)00465-1"},{"key":"4504_CR33","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jacc.2013.10.067","volume":"63","author":"S Brinker","year":"2014","unstructured":"Brinker, S. et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J. Am. Coll. Cardiol. 63, 834\u2013835 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4504_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/17512433.2025.2450257","volume":"18","author":"I Kacirova","year":"2025","unstructured":"Kacirova, I., Lazarova, M., Urinovska, R., Dodulik, J. & Vaclavik, J. Analysis of serum concentrations of metoprolol and its metabolite alpha-hydroxymetoprolol in patients with heart failure with reduced ejection fraction: a pilot study in routine health care. Expert Rev. Clin. Pharmacol. 18, 89\u201399 (2025).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"4504_CR35","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","volume":"10","author":"DE Morisky","year":"2008","unstructured":"Morisky, D. E., Ang, A., Krousel-Wood, M. & Ward, H. J. Predictive validity of a medication adherence measure in an outpatient setting. J. Clin. Hypertens. (Greenwich) 10, 348\u2013354 (2008).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"4504_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2022.03.009","volume":"10","author":"JH Butt","year":"2022","unstructured":"Butt, J. H. et al. Effects of dapagliflozin according to the heart failure collaboratory medical therapy score. Insights From DAPA-HF. JACC Heart Fail. 10, 543\u2013555 (2022).","journal-title":"JACC Heart Fail."},{"key":"4504_CR37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamacardio.2020.0640","volume":"5","author":"M Fiuzat","year":"2020","unstructured":"Fiuzat, M. et al. Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 5, 757\u2013764 (2020).","journal-title":"JAMA Cardiol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04504-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:01:53Z","timestamp":1786629713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04504-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4504"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04504-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.P. has received research funding (to the institution) from American Heart Association, Applied Therapeutics, Roche, Ultromics, Gilead Sciences, Bayer and AstraZeneca; has received honoraria as an advisor, consultant or speaker for Tricog Health Inc., Lilly, Rivus, Roche Diagnostics, Axon Therapies, Edward Lifesciences, Science37, Novo Nordisk, Bayer, Medical AI, AstraZeneca, Baylor Scott and White Research Institute, Boehringer Ingelheim, iRhythm Technologies, Tourmaline Bio, Merck, Sarfez Pharmaceuticals, Ultromics, Kardigan, Tenax Pharma, Alnylam, Abbott, Kilele Health, Anumana, Acorai, Novartis and Antlia Biosciences. A.P. is a coinventor on a Polypill for Heart Failure US provisional patent application (63\/912,172) filed November 2025. N.K. has received consultant fees from Heart Test Laboratories, Tricog Health, Idorsia Pharmaceuticals and Science37. M.W.S. reports nonfinancial support from Merck, honoraria outside the present study from Idorsia and Otsuka, is an advisor for AccurKardia, is on the executive board for descendantsDNA and is the founder of ReCODE Medical. A.C. has received grant funding outside the present study from Novo Nordisk, Lilly USA and Sarfez Pharmaceuticals. Z.L.C. reports grants from AstraZeneca and personal fees from Abiomed, Vectorious, Kestra Medical Technologies, Reprieve Cardiovascular, WhiteSwell and Lexicon Pharmaceuticals. D.K.G. has received honoraria as an advisor to Novo Nordisk and research support from the NHLBI (R01HL153607, R01HL145293, R01HL133860). M.T.H. has served as a consultant for Imricor Medical Systems Inc. T.J.W. is named as a coinventor on a Polypill for Heart Failure US provisional patent application (63\/912,172) filed November 2025 and another application related to technologies for producing combination pills. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}